Biocon Ltd

Biocon Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Biocon Ltd

₹ 358 1.84%
01 Jul 4:01 p.m.
biocon.com BSE: 532523 NSE: BIOCON
About

Biocon is engaged in the business of manufacture of biotechnology products and research services.(Source : 202003-01 Annual Report Page No:195)

Key Points

Business Segments
1.Biosimilars (~60% in FY24 vs ~50% in FY23):[1] Managed by Biocon Biologics, this segment has a portfolio of 20 biosimilars spanning across oncology, immunology, diabetes and other therapeutic areas. [2] It has gained market share in its key products, including bTrastuzumab, bPegfilgrastim, bGlargine, and bBevacizumab in the advanced markets. [3][4] It has a pipeline of 20+ molecules to be launched by 2030. [5]

Website BSE NSE
  • Market Cap ₹ 42,940 Cr.
  • Current Price ₹ 358
  • High / Low ₹ 360 / 218
  • Stock P/E 398
  • Book Value ₹ 90.9
  • Dividend Yield 0.14 %
  • ROCE 2.66 %
  • ROE 0.99 %
  • Face Value ₹ 5.00
Edit ratios

Pros

  • Company has been maintaining a healthy dividend payout of 42.1%

Cons

  • Stock is trading at 3.93 times its book value
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 3.56% over past five years.
  • Company has a low return on equity of 0.63% over last 3 years.
  • Earnings include an other income of Rs.208 Cr.
  • Company has high debtors of 180 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
492 383 365 473 518 442 490 555 507 513 519 563 533
425 359 388 439 491 439 462 518 551 441 452 492 480
Operating Profit 67 24 -23 34 26 3 28 37 -44 72 67 71 52
OPM % 14% 6% -6% 7% 5% 1% 6% 7% -9% 14% 13% 13% 10%
45 49 40 37 61 49 1,108 60 1,918 56 64 48 39
Interest 0 0 0 0 0 0 0 21 48 48 55 56 40
Depreciation 25 26 26 28 28 29 30 29 29 30 31 31 30
Profit before tax 86 46 -9 43 59 22 1,106 46 1,796 50 46 33 22
Tax % 22% 37% 29% 41% 36% 34% 11% 24% -1% 6% 25% 27% 36%
68 29 -7 26 38 15 988 35 1,811 47 35 24 14
EPS in Rs 0.56 0.24 -0.05 0.21 0.32 0.12 8.23 0.29 15.08 0.39 0.29 0.20 0.12
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
1,938 2,202 2,242 2,302 2,588 2,419 1,786 1,988 2,028 1,738 1,993 2,127
1,532 1,729 1,812 1,880 1,996 2,101 1,575 1,702 1,716 1,677 1,969 1,865
Operating Profit 406 473 430 422 592 318 210 286 312 61 24 263
OPM % 21% 21% 19% 18% 23% 13% 12% 14% 15% 4% 1% 12%
38 61 127 279 99 125 422 366 150 187 3,134 208
Interest 1 1 1 2 4 1 3 1 0 0 70 199
Depreciation 95 124 128 140 151 136 92 98 104 108 117 121
Profit before tax 347 409 428 559 536 306 537 553 359 140 2,971 150
Tax % 21% 21% 16% 34% 3% 22% 8% 20% 22% 38% 4% 21%
276 324 361 369 519 238 493 441 280 86 2,848 119
EPS in Rs 2.30 2.70 3.01 3.07 4.33 1.99 4.11 3.67 2.34 0.72 23.72 0.99
Dividend Payout % 54% 31% 28% 27% 12% 25% 12% 0% 0% 70% 6% 50%
Compounded Sales Growth
10 Years: 0%
5 Years: 4%
3 Years: 2%
TTM: 7%
Compounded Profit Growth
10 Years: -10%
5 Years: -20%
3 Years: -27%
TTM: 909%
Stock Price CAGR
10 Years: 15%
5 Years: 8%
3 Years: -4%
1 Year: 35%
Return on Equity
10 Years: 4%
5 Years: 2%
3 Years: 1%
Last Year: 1%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 100 100 100 100 100 300 300 600 600 600 600 600
Reserves 2,107 2,318 2,484 5,897 6,441 6,439 6,815 6,937 7,307 7,493 10,316 10,312
131 121 82 370 134 133 71 4 3 77 1,301 2,043
675 679 667 732 794 855 1,054 770 664 699 813 813
Total Liabilities 3,013 3,218 3,333 7,098 7,469 7,727 8,240 8,311 8,574 8,869 13,030 13,768
851 949 914 894 938 903 1,101 793 798 870 961 973
CWIP 51 102 58 172 241 318 254 152 179 285 344 545
Investments 619 493 165 3,853 3,888 4,199 4,093 4,953 5,413 5,280 9,271 9,318
1,492 1,674 2,196 2,179 2,402 2,307 2,792 2,413 2,184 2,434 2,454 2,932
Total Assets 3,013 3,218 3,333 7,098 7,469 7,727 8,240 8,311 8,574 8,869 13,030 13,768

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
348 186 125 208 186 355 110 387 571 48 219 -123
-87 51 145 -313 104 -553 315 -189 -721 -302 -1,173 -296
-147 -187 -158 73 -238 -55 -208 -129 28 112 1,039 344
Net Cash Flow 114 50 112 -32 52 -252 217 69 -122 -142 86 -76

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 80 82 90 80 113 112 184 105 109 147 121 180
Inventory Days 146 131 148 187 190 195 371 236 197 245 208 260
Days Payable 108 99 109 146 159 202 298 230 170 172 180 175
Cash Conversion Cycle 119 115 129 121 144 105 257 111 136 220 148 265
Working Capital Days 55 65 85 78 108 87 214 154 122 181 152 255
ROCE % 16% 17% 17% 10% 8% 4% 5% 5% 5% 2% 2%

Shareholding Pattern

Numbers in percentages

3 Recently
Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
60.64% 60.64% 60.64% 60.64% 60.64% 60.64% 60.64% 60.64% 60.64% 60.64% 60.64% 60.64%
15.91% 15.74% 16.00% 15.62% 16.31% 15.79% 14.42% 10.20% 9.52% 7.97% 6.55% 5.63%
7.52% 7.44% 7.37% 8.36% 7.72% 7.76% 8.63% 11.89% 12.59% 14.08% 14.51% 13.69%
15.02% 15.46% 15.34% 14.76% 14.60% 15.17% 15.74% 16.70% 16.77% 16.92% 17.96% 19.74%
0.91% 0.72% 0.65% 0.63% 0.73% 0.63% 0.58% 0.55% 0.49% 0.39% 0.33% 0.32%
No. of Shareholders 3,38,8273,63,4473,64,5023,47,9113,41,0163,69,8163,91,3824,11,0864,12,4414,15,0464,34,3394,70,261

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls